TTLL1-AS1: A Drug Target / Disease Biomarker (G100506679)

Target Name: TTLL1-AS1

NCBI ID: G100506679

TTLL1-AS1

Other Name(s): TTLL1 antisense RNA 1

TTLL1-AS1: A Drug Target / Disease Biomarker

TTLL1-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell lymphoma 1 (TLL1) family, which is characterized by the presence of a unique translocation event involving the T-cell receptor alpha chain and the BCR-Abl fusion gene. This translocation event gives rise to a unique gene fusion that is not found in any other known T-cell receptor alpha chain genes.

TTLL1-AS1 is of particular interest as a potential drug target or biomarker because of its unique expression patterns and the involvement of the TLL1 family in the development and progression of various diseases. In addition, its expression has been implicated in the development and progression of neurodegenerative diseases, which makes it an attractive target for therapeutic intervention.

TTLL1-AS1 is expressed in a variety of tissues and organs, including the brain, heart, and kidneys. It is highly expressed in the brain, where it is present in the postsynaptic density of microglia, astrocytes, and pericytes. It is also expressed in the heart, where it is present in the intercellular junctions of cardiac muscle cells. Additionally, it is expressed in the kidneys, where it is present in the podocytes.

The unique translocation event that gives rise to TTLL1-AS1 has been implicated in the development and progression of various diseases. For example, it has been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the buildup of neurofibrillary tangles, which are thought to be caused by the abnormal aggregation of the T-cell receptor alpha chain and the BCR-Abl fusion gene.

In addition to its involvement in neurodegenerative diseases, TTLL1-AS1 is also thought to be involved in the development and progression of other diseases. For example, it has been implicated in the development of various types of cancer, such as leukemia and melanoma. These diseases are characterized by the uncontrolled growth and proliferation of cells, which is thought to be caused by the abnormal activation of various signaling pathways.

TTLL1-AS1 is also of interest as a potential biomarker because of its expression patterns. The TLL1 family is characterized by the presence of a unique translocation event that gives rise to a unique gene fusion. This event is not found in any other known T-cell receptor alpha chain genes, which makes TTLL1-AS1 an attractive candidate for diagnostic and therapeutic applications.

In addition, the expression of TTLL1-AS1 has been implicated in the development and progression of various diseases, which makes it an attractive target for therapeutic intervention. For example, the abnormal activation of various signaling pathways, such as the T-cell receptor alpha chain and the BCR-Abl fusion gene, is thought to be a key driver of the development and progression of these diseases. By targeting these signaling pathways, therapeutic interventions may be able to alleviate the symptoms and improve the quality of life for individuals with these diseases.

In conclusion, TTLL1-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell lymphoma 1 (TLL1) family, which is characterized by the presence of a unique translocation event involving the T-cell receptor alpha chain and the BCR-Abl fusion gene. This translocation event gives rise to a unique gene fusion that is not found in any other known T-cell receptor alpha chain genes. TTLL1-AS1 is of particular interest as a potential drug target or biomarker because of its unique expression patterns and the involvement of the TLL1 family in the development and progression of various diseases. Its expression has also been implicated in the development and progression of neurodegenerative diseases, as

Protein Name: TTLL1 Antisense RNA 1

The "TTLL1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets